NZ706218A - Pyrazolopyrimidine jak inhibitor compounds and methods - Google Patents
Pyrazolopyrimidine jak inhibitor compounds and methodsInfo
- Publication number
- NZ706218A NZ706218A NZ706218A NZ70621810A NZ706218A NZ 706218 A NZ706218 A NZ 706218A NZ 706218 A NZ706218 A NZ 706218A NZ 70621810 A NZ70621810 A NZ 70621810A NZ 706218 A NZ706218 A NZ 706218A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- inhibitor compounds
- jak inhibitor
- formula
- compounds
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- 208000037244 polycythemia vera Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Disclosed are pyrazolopyrimidine compounds of formula (I) and methods for their preparation. The compounds of formula (I) are Janus kinase (JAK) inhibitors, and useful for treating cancer, polycythaemia Vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukaemia (CML), rheumatoid arthritis, inflammatory bowel syndrome, Chron’s disease, psoriasis, contact dermatitis or delayed hypersensitivity reactions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ719972A NZ719972A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22291809P | 2009-07-02 | 2009-07-02 | |
NZ622283A NZ622283A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ706218A true NZ706218A (en) | 2016-08-26 |
Family
ID=43411778
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ738778A NZ738778A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
NZ622283A NZ622283A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
NZ706218A NZ706218A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
NZ719972A NZ719972A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ738778A NZ738778A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
NZ622283A NZ622283A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ719972A NZ719972A (en) | 2009-07-02 | 2010-07-02 | Pyrazolopyrimidine jak inhibitor compounds and methods |
Country Status (35)
Country | Link |
---|---|
US (6) | US8999998B2 (en) |
EP (3) | EP3333169B1 (en) |
JP (4) | JP5769261B2 (en) |
KR (3) | KR20180108858A (en) |
CN (2) | CN102482284B (en) |
AU (1) | AU2010266188B2 (en) |
BR (1) | BRPI1010197A2 (en) |
CA (1) | CA2767097A1 (en) |
CL (1) | CL2012000001A1 (en) |
CO (1) | CO6491081A2 (en) |
CR (2) | CR20170115A (en) |
DK (1) | DK2448941T3 (en) |
EC (1) | ECSP12011645A (en) |
ES (1) | ES2657839T3 (en) |
HR (1) | HRP20180157T1 (en) |
HU (1) | HUE035537T2 (en) |
IL (3) | IL217224B (en) |
IN (1) | IN2012DN00755A (en) |
LT (1) | LT2448941T (en) |
MA (1) | MA33502B1 (en) |
MX (1) | MX2012000169A (en) |
MY (1) | MY160156A (en) |
NO (1) | NO2448941T3 (en) |
NZ (4) | NZ738778A (en) |
PE (2) | PE20151249A1 (en) |
PH (1) | PH12015500666A1 (en) |
PL (1) | PL2448941T3 (en) |
PT (1) | PT2448941T (en) |
RS (1) | RS56671B1 (en) |
RU (2) | RU2567238C2 (en) |
SG (2) | SG177454A1 (en) |
SI (1) | SI2448941T1 (en) |
UA (1) | UA110324C2 (en) |
WO (1) | WO2011003065A2 (en) |
ZA (2) | ZA201200490B (en) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3184526T (en) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
BRPI0914404A2 (en) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compounds, pharmaceutical composition and method for treating or mitigating the severity of a disease or condition responsive to inhibition of jak kinase activity in a patient" |
CN106967070A (en) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | It is used as the compound of JAK inhibitor |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
TWI766281B (en) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
ES2601004T3 (en) | 2010-04-07 | 2017-02-13 | F. Hoffmann-La Roche Ag | Pirazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
PE20130216A1 (en) | 2010-05-21 | 2013-02-27 | Incyte Corp | TOPICAL FORMULATION FOR A JAK INHIBITOR |
CA2802641C (en) * | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
EP2635278B1 (en) | 2010-11-03 | 2019-12-11 | Dow AgroSciences LLC | Pesticidal compositions and processes related thereto |
US8609669B2 (en) * | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
AR083933A1 (en) | 2010-11-19 | 2013-04-10 | Incyte Corp | PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS |
EP2688872A4 (en) * | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
US8859549B2 (en) | 2011-05-13 | 2014-10-14 | Abbvie, Inc. | Potassium channel modulators |
EA201490042A1 (en) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
TWI570117B (en) | 2011-09-27 | 2017-02-11 | 赫孚孟拉羅股份公司 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
CN103930427B (en) | 2011-09-30 | 2016-03-09 | 昂科迪塞恩股份有限公司 | Large ring FLT3 kinase inhibitor |
MX355431B (en) | 2011-10-26 | 2018-04-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto. |
WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
JP6463670B2 (en) | 2012-04-27 | 2019-02-06 | ダウ アグロサイエンシィズ エルエルシー | Agrochemical compositions and methods relating thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
JP2015528435A (en) * | 2012-08-10 | 2015-09-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pyrazole carboxamide compounds, compositions and methods of use |
CN103073549A (en) * | 2012-09-07 | 2013-05-01 | 苏州康润医药有限公司 | 3-bromopyrazol[1,5-alpha]pyrimidine-2-formic acid synthesis process |
CN104640850A (en) * | 2012-10-26 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 3,4-disubstituted 1 H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
ES2946360T3 (en) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases |
EP2951590A1 (en) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
HUE057262T2 (en) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Processes and intermediates for making a jak inhibitor |
WO2014143241A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2014143240A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9102654B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
US9108946B2 (en) | 2013-10-17 | 2015-08-18 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
WO2015058024A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
CA2925954A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
EP3057428A4 (en) | 2013-10-17 | 2017-05-17 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
WO2015058020A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
EP3057431A4 (en) | 2013-10-17 | 2017-04-05 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
US9491944B2 (en) | 2013-10-22 | 2016-11-15 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
CN105792651A (en) | 2013-10-22 | 2016-07-20 | 美国陶氏益农公司 | Pesticidal compositions and related methods |
JP2016534068A (en) | 2013-10-22 | 2016-11-04 | ダウ アグロサイエンシィズ エルエルシー | Synergistic pest control compositions and related methods |
NZ719776A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
AU2014340413B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
MX2016005310A (en) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods. |
AU2014340432B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
EP3060055A4 (en) | 2013-10-22 | 2017-03-29 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
TW201517797A (en) | 2013-10-22 | 2015-05-16 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
US9144241B2 (en) | 2013-10-22 | 2015-09-29 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
JP2016535026A (en) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | Synergistic pest control compositions and related methods |
AU2014340409B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
TW201519776A (en) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
TW201519779A (en) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
RU2656888C2 (en) | 2013-10-22 | 2018-06-07 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticide compositions and related methods |
RU2656889C2 (en) | 2013-10-22 | 2018-06-07 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Pesticidal compositions and related methods |
AR098100A1 (en) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | PESTICIDED COMPOSITIONS AND RELATED METHODS |
BR112016010041B1 (en) * | 2013-11-08 | 2023-04-18 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND WITH AN IRAK-4 INHIBITORY ACTION, PHARMACEUTICAL COMPOSITION, AND USE OF THE COMPOUND |
CN104650092B (en) * | 2013-11-16 | 2017-11-10 | 广东东阳光药业有限公司 | Substituted heteroaryl compound and combinations thereof and purposes |
WO2015084384A1 (en) * | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
RU2687276C2 (en) * | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Compounds suitable for use as atr kinase inhibitors |
TW201620911A (en) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
CN106413716B (en) * | 2014-04-08 | 2020-03-27 | 因赛特公司 | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors |
MX2016015062A (en) * | 2014-05-23 | 2017-02-27 | Hoffmann La Roche | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors. |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
LT3152212T (en) * | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
EP3174856A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CA2954631A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
WO2016018443A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
EP3183238A4 (en) | 2014-08-19 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
WO2016039781A1 (en) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016202898A1 (en) * | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
CA2998469A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
BR112018009252A2 (en) | 2015-11-06 | 2018-11-06 | Samumed Llc | osteoarthritis treatment |
TW201720828A (en) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | Therapeutic compounds and compositions, and methods of use thereof |
CN108473501B (en) * | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | Therapeutic compounds, compositions and methods of use thereof |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
SI3464285T1 (en) | 2016-06-01 | 2023-02-28 | Biosplice Therapeutics, Inc. | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo(4,5-c)pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN106008525B (en) * | 2016-06-16 | 2018-08-07 | 南京工业大学 | A kind of small molecule organic nano tumor thermal therapy reagent and preparation method thereof |
US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
CN110325036B (en) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | Process for preparing pesticidal compounds |
KR20190100337A (en) * | 2016-12-29 | 2019-08-28 | 에프. 호프만-라 로슈 아게 | Pyrazolopyrimidine Compounds and Methods of Use thereof |
CR20190332A (en) * | 2017-01-17 | 2019-09-13 | Astrazeneca Ab | Jak1 selective inhibitors |
EP3596072B1 (en) | 2017-03-14 | 2022-06-22 | F. Hoffmann-La Roche AG | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
PL233595B1 (en) * | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Derivatives of pyrazolo[1,5-a]pyrimidine as inhibitors of kinase JAK |
CR20190520A (en) | 2017-05-22 | 2020-01-21 | Hoffmann La Roche | Therapeutic compounds and compositions, and methods of use thereof |
US20180334465A1 (en) * | 2017-05-22 | 2018-11-22 | Genentech, Inc. | Therapeutic compounds and compositions, and methods of use thereof |
CA3070010A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Cropscience Aktiengesellschaft | Substituted 3-heteroaryloxy-1h-pyrazoles and salts thereof and their use as herbicidal active substances |
CN107686456B (en) * | 2017-07-25 | 2018-10-23 | 杭州师范大学 | A kind of quinolione key intermediate ethyl ester aminate and its preparation method and application |
CN109422751B (en) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | Compound with activity of degrading tyrosine protein kinase JAK3 |
AR113922A1 (en) | 2017-12-08 | 2020-07-01 | Incyte Corp | LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS |
CN111587250A (en) * | 2018-01-15 | 2020-08-25 | 豪夫迈·罗氏有限公司 | Pyrazolopyrimidine compounds as JAK inhibitors |
JP7133023B2 (en) * | 2018-01-17 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | PI4KIII beta inhibitor |
CN112105608B (en) | 2018-01-30 | 2023-07-14 | 因赛特公司 | Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one |
JPWO2019172243A1 (en) | 2018-03-07 | 2020-04-16 | 三菱ケミカル株式会社 | Transparent resin composition, resin molding, lamp cover, vehicle lamp cover, combination lamp cover and vehicle |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
MA52208A (en) * | 2018-04-13 | 2021-02-17 | Incyte Corp | BIOMARKERS FOR GRAFT-HOST DISEASE AGAINST HOST |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US20230000842A1 (en) * | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
EA202192575A1 (en) | 2019-03-21 | 2022-01-14 | Онксео | DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT |
EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
CN114008051A (en) | 2019-06-18 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof |
CN114026096A (en) * | 2019-06-18 | 2022-02-08 | 豪夫迈·罗氏有限公司 | Tetrazole-substituted pyrazolopyrimidine JAK kinase inhibitor and application thereof |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022256358A1 (en) | 2021-06-03 | 2022-12-08 | Genentech, Inc. | Process for preparing medicaments |
CN115466227A (en) * | 2022-06-30 | 2022-12-13 | 杭州国瑞生物科技有限公司 | Preparation method of 3- (chloromethyl) -1-methyl-1H-1,2,4-triazole hydrochloride |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES517193A0 (en) | 1981-11-10 | 1983-12-01 | Wellcome Found | A PROCEDURE FOR THE PREPARATION OF NEW IMIDAZO DERIVATIVES (4,5-C) PIRIDINA. |
US4602035A (en) | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
US4847256A (en) | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
US7070972B1 (en) | 1995-01-13 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Janus family kinases and identification of immune modulators |
US7091020B1 (en) | 1995-12-05 | 2006-08-15 | Incyte Corporation | Human Jak2 kinase |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2791562B1 (en) | 1999-03-29 | 2004-03-05 | Oreal | TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AND A MONOCYCLIC POLYAMINOPYRIMIDINE AS OXIDATION BASES AND A COUPLER, AND DYEING METHODS |
NZ516260A (en) | 1999-07-02 | 2004-08-27 | Eisai Co Ltd | Fused imidazole compounds and remedies for diabetes mellitus |
CN1195755C (en) * | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | Pyrrolo [2,3-d] pyrimidine compounds |
MXPA04010441A (en) | 2002-04-23 | 2005-02-14 | Shionogi & Co | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME. |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | Antiinflammation agents |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
SE0301372D0 (en) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
ATE508129T1 (en) * | 2004-03-30 | 2011-05-15 | Vertex Pharma | AZAINDOLS SUITABLE AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES |
EP1748772A2 (en) | 2004-04-09 | 2007-02-07 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
US7517888B2 (en) | 2004-04-28 | 2009-04-14 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
WO2006004702A1 (en) | 2004-06-25 | 2006-01-12 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
ES2354824T3 (en) | 2004-11-04 | 2011-03-18 | Vertex Pharmaceuticals, Inc. | PIRAZOLO [1,5-A] USEFUL PYRIMIDINS AS INHIBITORS OF KINASE PROTEINS. |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
WO2007039797A1 (en) | 2005-10-03 | 2007-04-12 | Pfizer Products Inc. | Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis |
CA2624500A1 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2007041712A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
US8101625B2 (en) | 2005-10-21 | 2012-01-24 | Exelixis, Inc. | Pyrimidinones as Casein Kinase II (CK2) modulators |
RU2008127263A (en) | 2005-12-08 | 2010-01-20 | Новартис АГ (CH) | Pyrazole [1,5-a] Pyridine-3-Carboxylic Acids As Inhibitors of EphB-and VEGFR2-Kinase |
US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
AU2007235487A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
KR20160112018A (en) | 2006-06-02 | 2016-09-27 | 니뽄 신야쿠 가부시키가이샤 | 9,10-secopregnane derivative and pharmaceutical |
AR061793A1 (en) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION |
PE20080403A1 (en) | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
CN101522682A (en) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | Heterocyclic compounds as antiinflammatory agents |
EP2102211A2 (en) | 2006-11-20 | 2009-09-23 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
KR20100090772A (en) * | 2007-10-12 | 2010-08-17 | 인게니움 파르마코이티칼스 게엠베하 | Inhibitors of protein kinases |
EA019869B1 (en) | 2007-11-28 | 2014-06-30 | Дана Фарбер Кансер Инститьют, Инк. | Small molecule myristate inhibitors of tyrosine kinase bcr-abl and methods of use thereof |
JP2011507910A (en) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
WO2010019762A1 (en) | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Purine compounds as cannabinoid receptor blockers |
BRPI0914404A2 (en) * | 2008-10-31 | 2019-03-06 | Genentech Inc | "compounds, pharmaceutical composition and method for treating or mitigating the severity of a disease or condition responsive to inhibition of jak kinase activity in a patient" |
WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
NZ593951A (en) | 2009-02-06 | 2013-01-25 | Ortho Mcneil Janssen Pharm | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
TWI461425B (en) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
CN102666545B (en) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
WO2011113802A2 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
JP2013525392A (en) | 2010-04-30 | 2013-06-20 | セルゾーム リミティッド | Pyrazole compounds as JAK inhibitors |
-
2010
- 2010-02-07 UA UAA201201035A patent/UA110324C2/en unknown
- 2010-07-02 KR KR1020187027109A patent/KR20180108858A/en not_active Application Discontinuation
- 2010-07-02 ES ES10794815.0T patent/ES2657839T3/en active Active
- 2010-07-02 KR KR1020127002790A patent/KR101825754B1/en active IP Right Grant
- 2010-07-02 US US13/382,145 patent/US8999998B2/en active Active
- 2010-07-02 MA MA34594A patent/MA33502B1/en unknown
- 2010-07-02 DK DK10794815.0T patent/DK2448941T3/en active
- 2010-07-02 IN IN755DEN2012 patent/IN2012DN00755A/en unknown
- 2010-07-02 NO NO10794815A patent/NO2448941T3/no unknown
- 2010-07-02 KR KR1020177012984A patent/KR101903305B1/en active IP Right Grant
- 2010-07-02 EP EP17192475.6A patent/EP3333169B1/en active Active
- 2010-07-02 CR CR20170115A patent/CR20170115A/en unknown
- 2010-07-02 EP EP19211640.8A patent/EP3670514A1/en not_active Withdrawn
- 2010-07-02 SI SI201031625T patent/SI2448941T1/en unknown
- 2010-07-02 PE PE2015000692A patent/PE20151249A1/en not_active Application Discontinuation
- 2010-07-02 PL PL10794815T patent/PL2448941T3/en unknown
- 2010-07-02 MY MYPI2011006384A patent/MY160156A/en unknown
- 2010-07-02 HU HUE10794815A patent/HUE035537T2/en unknown
- 2010-07-02 NZ NZ738778A patent/NZ738778A/en not_active IP Right Cessation
- 2010-07-02 BR BRPI1010197A patent/BRPI1010197A2/en not_active Application Discontinuation
- 2010-07-02 CN CN201080039041.1A patent/CN102482284B/en active Active
- 2010-07-02 RS RS20171278A patent/RS56671B1/en unknown
- 2010-07-02 RU RU2012103487/04A patent/RU2567238C2/en not_active IP Right Cessation
- 2010-07-02 AU AU2010266188A patent/AU2010266188B2/en not_active Ceased
- 2010-07-02 MX MX2012000169A patent/MX2012000169A/en active IP Right Grant
- 2010-07-02 PT PT107948150T patent/PT2448941T/en unknown
- 2010-07-02 WO PCT/US2010/040906 patent/WO2011003065A2/en active Application Filing
- 2010-07-02 EP EP10794815.0A patent/EP2448941B1/en active Active
- 2010-07-02 RU RU2015133989A patent/RU2675857C2/en not_active IP Right Cessation
- 2010-07-02 SG SG2011097623A patent/SG177454A1/en unknown
- 2010-07-02 CA CA2767097A patent/CA2767097A1/en not_active Abandoned
- 2010-07-02 PE PE2012000003A patent/PE20120575A1/en active IP Right Grant
- 2010-07-02 JP JP2012517917A patent/JP5769261B2/en active Active
- 2010-07-02 CN CN201510276276.7A patent/CN104910161B/en active Active
- 2010-07-02 NZ NZ622283A patent/NZ622283A/en not_active IP Right Cessation
- 2010-07-02 LT LTEP10794815.0T patent/LT2448941T/en unknown
- 2010-07-02 SG SG10201509607XA patent/SG10201509607XA/en unknown
- 2010-07-02 NZ NZ706218A patent/NZ706218A/en not_active IP Right Cessation
- 2010-07-02 NZ NZ719972A patent/NZ719972A/en not_active IP Right Cessation
-
2011
- 2011-12-27 IL IL217224A patent/IL217224B/en not_active IP Right Cessation
-
2012
- 2012-01-02 CL CL2012000001A patent/CL2012000001A1/en unknown
- 2012-01-20 ZA ZA2012/00490A patent/ZA201200490B/en unknown
- 2012-01-25 CO CO12011326A patent/CO6491081A2/en active IP Right Grant
- 2012-01-30 CR CR20120053A patent/CR20120053A/en unknown
- 2012-02-02 EC ECSP12011645 patent/ECSP12011645A/en unknown
-
2013
- 2013-10-02 ZA ZA2013/07356A patent/ZA201307356B/en unknown
-
2015
- 2015-02-06 US US14/615,873 patent/US20150152117A1/en not_active Abandoned
- 2015-03-25 PH PH12015500666A patent/PH12015500666A1/en unknown
- 2015-06-17 JP JP2015122441A patent/JP6312634B2/en active Active
- 2015-12-09 IL IL242999A patent/IL242999B/en not_active IP Right Cessation
-
2017
- 2017-06-20 US US15/627,847 patent/US20170283424A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000305A patent/JP2018083828A/en not_active Withdrawn
- 2018-01-15 IL IL256921A patent/IL256921A/en unknown
- 2018-01-26 HR HRP20180157TT patent/HRP20180157T1/en unknown
-
2019
- 2019-06-07 JP JP2019106948A patent/JP2019194199A/en active Pending
- 2019-09-05 US US16/561,432 patent/US20200002345A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/648,045 patent/US20220389020A1/en not_active Abandoned
-
2023
- 2023-11-13 US US18/507,678 patent/US20240150364A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ706218A (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
EA201391528A1 (en) | Thyrosine Kinase Inhibitors | |
EA027213B9 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
UA111075C2 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
EA201792529A1 (en) | Thyrosine Kinase Inhibitors | |
MX2011012369A (en) | Pyrazolopyrimidines and related heterocycles as kinase inhibitors. | |
MX2013013090A (en) | Aminopyrimidines as syk inhibitors. | |
MX2011012353A (en) | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS. | |
MX362855B (en) | Quinazolinone derivatives as parp inhibitors. | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
WO2013164061A8 (en) | Pyrrolotriazinone derivatives | |
WO2013163190A8 (en) | Dna-pk inhibitors | |
WO2012054364A3 (en) | Bicyclic diamines as janus kinase inhibitors | |
PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
WO2011080568A3 (en) | Novel pyrimidine compounds as mtor and p13k inhibitors | |
MX2011012037A (en) | Heteroaryl compounds as pikk inhibitors. | |
MX2019005232A (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors. | |
WO2007149427A3 (en) | Tyrosine kinase inhibitors | |
WO2008086462A3 (en) | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | |
MX2020003126A (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors. | |
CL2011002965A1 (en) | Compounds derived from substituted piperidines; preparation procedure; pharmaceutical composition; and use of said compounds for the treatment and / or prophylaxis of cardiovascular, thromboembolic disorders and / or tumors. | |
WO2018218197A3 (en) | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase | |
WO2009111354A3 (en) | Tyrosine kinase inhibitors | |
WO2015082376A3 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer | |
WO2012048258A3 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 JUL 2017 BY AJ PARK Effective date: 20170227 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUL 2018 BY THOMSON REUTERS Effective date: 20170621 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUL 2019 BY THOMSON REUTERS Effective date: 20180622 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUL 2020 BY THOMSON REUTERS Effective date: 20190620 |
|
LAPS | Patent lapsed |